Posted by SLS on July 24, 2015, at 15:54:02
In reply to Lou's urgent request to readers-huizhe » Uncouth, posted by Lou Pilder on July 24, 2015, at 14:09:56
Mr. Pilder.
Your research seems to be incomplete. Please review the following article with special attention paid to the quoted passages. You simply do not know enough to go out of your way to scare people. I think it would be more supportive to the community if you would match your tone to your level of knowledge.
- Scott----------------------------------------------------
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014120/
"The data indicate that nortriptyline and desipramine have the most pharmacologically desirable characteristics as noradrenaline reuptake inhibitors (NRIs), and as drugs with few interactions that are also safe when coadministered with either MAOIs or SSRIs."
"When tyramine is administered intravenously, blood pressure increases and this response is greatly potentiated by MAOIs. Tyramine utilizes, and requires, the NAT to enter the pre-synaptic terminal, where it then induces depolarization-independent release of NA. NRIs inhibit tyramine uptake and thus attenuate the response, which gives an in vivo measure of their NRI potency: indeed the NRIs with the highest affinity for the NAT (reboxetine, desipramine and nortriptyline; Table 3) have all been demonstrated to block this response almost completely, even when it has been potentiated in the presence of MAOIs"
----------------------------------------------------
Some see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1080645
URL: http://www.dr-bob.org/babble/20150629/msgs/1080743.html